Amsterdam-based contract drug developer Patheon has raised an eye-watering $625 million by offering 29.8 million shares at $21 a pop.

London-based investment and advisory firm GHO Capital has acquired proteomics and immune monitoring services provider Caprion Biosciences for an undisclosed…

After a strong 6 months that has seen the best growth spurt in its history, Lonza is raising its guidance for the rest of the year.

Germany’s hybrid CRO-biotech Evotec has had a better few months than expected as it announces stronger profits for 2016 ahead of its half-year results on Aug.…

A new paper published in the journal Computer argues that personal health information must be better secured with increased privacy settings--or risk PHI…

The personal genome company 23andMe has launched a new platform that will allow researchers to see and track certain genetic information from patients in their…

Israeli biotech Pluristem Therapeutics has chosen a “leading, global” CRO to help run its Phase I blood cancer trial--but the company is a little shy on…

The pharma services industry continues to buck a negative trend as Patheon sets its terms for an eye-watering $625 million initial public offering.